Asceneuron
Asceneuron SA is a clinical-stage Swiss biotech developing orally bioavailable O-GlcNAcase (OGA) inhibitor small molecules — ASN51 for Alzheimer's disease and ASN90 (licensed to Ferrer) for progressive supranuclear palsy — to halt tau and alpha-synuclein aggregation in neurodegenerative diseases.
- Company typePrivate
- Founded2012
- HeadquartersLausanne, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Asceneuron does
Asceneuron SA is a clinical-stage biotechnology company founded in 2012 as a spin-off of Merck Serono's Alzheimer's drug discovery portfolio and headquartered at the EPFL Innovation Park in Eysins, Switzerland, with a US office in Cambridge, Massachusetts. The company is developing orally bioavailable, brain-penetrant small-molecule inhibitors of O-GlcNAcase (OGA), an enzyme that regulates protein O-GlcNAcylation, with the goal of preventing toxic tau and alpha-synuclein aggregation that drives neurodegenerative disease progression. Its pipeline comprises two clinical-stage OGA inhibitors — ASN51 (advancing to Phase 2 in Alzheimer's disease, with planned expansion to Parkinson's disease and ALS) and ASN90 (out-licensed to Ferrer for progressive supranuclear palsy, an orphan tauopathy) — plus a preclinical M1 Positive Allosteric Modulator program targeting cognitive dysfunction in Parkinson's disease dementia, Lewy Body dementia, and frontotemporal dementia. Both ASN51 and ASN90 have completed Phase 1 trials demonstrating safety, tolerability, high CNS target engagement (confirmed via PET imaging), and once-daily oral dosing.
The company's business model is asset-centric: rather than commercializing products directly, Asceneuron advances compounds through clinical proof-of-concept and then either licenses them to pharmaceutical partners for late-stage development and global commercialization (as with ASN90/Ferrer) or retains rights for self-development through Phase 2 before seeking a commercialization partner (the stated plan for ASN51). Revenue mechanics are therefore milestone-driven licensing and royalties (upfront fees, development/regulatory/commercial milestones, tiered double-digit royalties on net sales) supplemented by non-dilutive grant funding from disease foundations (Alzheimer's Drug Discovery Foundation, Michael J. Fox Foundation, Cure PSP). End customers are ultimately patients with Alzheimer's, Parkinson's, PSP, ALS, and related dementias, served indirectly through healthcare systems and pharmaceutical partners rather than through direct sales channels. The company is privately held, venture-backed (Series A CHF 30M led by Sofinnova Partners in 2015; Series C $100M led by Novo Holdings in July 2024), and operates with 11–50 employees.
Asceneuron firmographics
Firmographics- Name
- Asceneuron
- Legal name
- Asceneuron SA
- Website
- https://asceneuron.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Asceneuron SA is a clinical-stage Swiss biotech developing orally bioavailable O-GlcNAcase (OGA) inhibitor small molecules — ASN51 for Alzheimer's disease and ASN90 (licensed to Ferrer) for progressive supranuclear palsy — to halt tau and alpha-synuclein aggregation in neurodegenerative diseases.
- Ownership category
- akta.pro rank
Asceneuron industry classification
Industry- Product category
- Neurodegenerative Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
Keywords
Where Asceneuron is headquartered
LocationHeadquarters
- HQ city
- Lausanne
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Asceneuron business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Licensing and Milestone Payments: Asceneuron generates revenue through licensing agreements where partners like Ferrer acquire worldwide rights to develop and commercialize drug candidates. Terms include upfront fees, development/regulatory/commercial milestone payments, and tiered double-digit royalties on net sales.
- Grant Funding: Non-dilutive funding from foundations including The Michael J. Fox Foundation (Parkinson's research), Alzheimer's Drug Discovery Foundation (ASN51 Phase I), and Cure PSP for research and clinical development.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Asceneuron product offering
Product offeringCore offering
Asceneuron discovers and develops orally administered small-molecule O-GlcNAcase (OGA) inhibitors as disease-modifying therapeutics for neurodegenerative disorders with high unmet medical needs, including Alzheimer's disease, Parkinson's disease, and orphan tauopathies such as Progressive Supranuclear Palsy (PSP). The company advances clinical-stage drug candidates internally and monetizes them through licensing partnerships with pharmaceutical companies and grants from research foundations.
Product overview
Asceneuron is a clinical-stage biotech company developing a pipeline of orally administered small molecule O-GlcNAcase (OGA) inhibitors designed to halt abnormal protein aggregation in the brain. The company's proprietary clinical pipeline consists of two OGA inhibitors: ASN51 (potential best-in-class for Alzheimer's disease and Parkinson's disease, with expansion to ALS) and ASN90 (licensed to Ferrer for Progressive Supranuclear Palsy). Both compounds have completed Phase 1 studies demonstrating CNS uptake and OGA enzyme occupancy. The company also has a preclinical M1 PAM program for cognitive dysfunction in dementia. Asceneuron's approach targets both tau and alpha-synuclein pathologies to address neurodegenerative proteinopathies.
Differentiator
Problem solved
Functional benefit
Products and services
- ASN51 Asceneuron's next-generation O-GlcNAcase (OGA) inhibitor and lead clinical asset. An oral small molecule designed to inhibit the OGA enzyme and prevent tau and alpha-synuclein protein aggregation in the brain. ASN51 has completed five Phase 1 clinical trials demonstrating complete CNS uptake and high OGA enzyme occupancy confirmed by PET imaging, with a once-daily oral dosing profile. It is being advanced into Phase 2 development for Alzheimer's disease with planned expansion to Parkinson's disease and ALS.
- ASN90 (formerly ASN120290) Clinical-stage O-GlcNAcase inhibitor in-licensed to Ferrer for the treatment of Progressive Supranuclear Palsy (PSP), an orphan tau-related neurodegenerative disease. ASN90 has received Orphan Drug Designation from both the US FDA and the European EMA, and has completed three Phase 1 clinical studies including safety/tolerability studies in healthy volunteers and a PET CNS target engagement study.
- M1 PAM (Positive Allosteric Modulator) Preclinical-stage M1 muscarinic receptor positive allosteric modulator program targeting cognitive dysfunction in dementia indications including Parkinson's disease dementia (PDD), Lewy Body Dementia (LBD), and Frontotemporal dementia (FTD). The program is currently at 25% development stage.
Quantifiable outcome
- Completed 5 Phase 1 clinical trials for ASN51 demonstrating complete CNS uptake and high OGA enzyme occupancy
- +2 more outcomes
Companies that use Asceneuron
Customer profileSegments4 records
Ideal customer profiles2 records
Asceneuron technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Asceneuron partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Critical Path Institute (CPAD Consortium)coreAsceneuron joined the Critical Path for Alzheimer's Disease (CPAD) Consortium, collaborating with industry, academic, and regulatory experts to advance biomarkers for AD drug development, including tau PET imaging. The consortium has over 100,000 patient-level records and works with 370+ institutions worldwide.
- FerrercoreFerrer acquired exclusive worldwide rights to develop and commercialize ASN90 for progressive supranuclear palsy (PSP). Terms include upfront fee, multiple development/regulatory/commercial milestone payments, and tiered double-digit royalties on worldwide net sales. Ferrer will conduct Phase II clinical studies.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Asceneuron competitors and assessment
Company assessmentBroad incumbents
- Eisai: Co-developer with Biogen of Leqembi (lecanemab) for Alzheimer's with deep CNS franchise and tau-related research. Comparable as a leading Alzheimer's therapeutics developer and a potential strategic partner or acquirer for Asceneuron's ASN51.
- Biogen: Major neuroscience-focused pharma commercializing Leqembi (lecanemab) with Eisai for Alzheimer's and historically invested in tau programs. Comparable as both a competitor in neurodegenerative diseases and a potential acquirer of CNS-focused biotechs like Asceneuron.
- Merck & Co: Large pharma whose former Serono division originally developed the OGA inhibitor portfolio from which Asceneuron was spun out in 2012. Comparable as both a historical OGA program originator (MK-8719 program) and a potential strategic acquirer given CNS franchise interest.
- Roche: Large pharma with the tau-targeting program semorinemab in Alzheimer's and broader neuroscience pipeline. Comparable as a major incumbent in neurodegenerative drug development competing for the same patient population and partnership opportunities as Asceneuron.
- Eli Lilly: Large pharma with multiple Alzheimer's programs including Kisunla (donanemab) and historic tau-targeting programs. Comparable to Asceneuron as a key competitor in the Alzheimer's/tau space with vastly greater resources and commercialization capabilities.
Direct peers
- Prothena: Clinical-stage biotech developing therapeutics targeting tau, alpha-synuclein, and other proteinopathies for Alzheimer's, Parkinson's, and ATTR amyloidosis. Directly comparable to Asceneuron given dual tau/synuclein focus and similar clinical-stage profile.
- AC Immune: Clinical-stage biotech developing tau-targeted immunotherapies and small molecules for neurodegenerative diseases. Highly comparable to Asceneuron given shared focus on tau pathology, clinical-stage pipeline, and similar target indications (Alzheimer's, Parkinson's).
Emerging players
- Ionis Pharmaceuticals: Clinical-stage antisense oligonucleotide (ASO) leader with active programs targeting tau for Alzheimer's and other CNS indications. Comparable to Asceneuron as a clinical-stage neuroscience peer addressing tau pathology through a different (oligonucleotide) modality.
- Wave Life Sciences: Clinical-stage biotech developing antisense oligonucleotide (ASO) therapies targeting tau and alpha-synuclein for Alzheimer's and Huntington's disease. Comparable as a clinical-stage neuroscience peer using different modality to target similar proteinopathies as Asceneuron's ASN51.
- Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's and Alzheimer's, with a focus on lysosomal function and protein homeostasis. Comparable to Asceneuron given similar clinical-stage neuroscience profile and big-pharma partnerships.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Asceneuron social profiles
Digital presenceAsceneuron financial estimates
Financial estimateRevenue estimate
Valuation estimate
Asceneuron leadership team
Management profileNumber of profiles
Profiles9 records
Asceneuron funding detail
Funding detailFunding overview
Funding rounds4 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Asceneuron M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Asceneuron
What does Asceneuron do?
Asceneuron discovers and develops orally administered small-molecule O-GlcNAcase (OGA) inhibitors as disease-modifying therapeutics for neurodegenerative disorders with high unmet medical needs, including Alzheimer's disease, Parkinson's disease, and orphan tauopathies such as Progressive Supranuclear Palsy (PSP). The company advances clinical-stage drug candidates internally and monetizes them through licensing partnerships with pharmaceutical companies and grants from research foundations.
Is Asceneuron a public or private company?
Asceneuron is a private company. It is classified as venture growth investor backed and is currently operating.
When was Asceneuron founded?
Asceneuron was founded in 2012. It employs 11 to 50 people.
Where is Asceneuron based?
Asceneuron is headquartered in Lausanne, Switzerland, in the Europe region.
How does Asceneuron make money?
Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are grant Funding.
Who are Asceneuron's main competitors?
Broad incumbents on record are Eisai, Biogen, Merck & Co, Roche and Eli Lilly. Direct peers are Prothena and AC Immune. Emerging players are Ionis Pharmaceuticals, Wave Life Sciences and Denali Therapeutics.
Does Asceneuron have an API?
No public API is recorded for Asceneuron.
What industry is Asceneuron in?
Asceneuron's product category is Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2833.